Karen Akinsanya
Director; President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships · 4 filings · Latest: Sep 17, 2026
Nautilus Biotechnology, Inc.
Schrodinger, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
SDGR | Karen Akinsanya | President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships | Sep 17, 2026 | Sale | $29.37 | 31,599 | $928.0K | 69,956 | |
SDGR | Karen Akinsanya | President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships | Sep 17, 2026 | Option Exercise | $4.34 | 31,599 | $137.1K | 101,555 | |
SDGR | KAREN OLUFUNMILYO AKINSANYA-AKIWUMI | — | Sep 17, 2026 | Proposed Sale | $23.93 | 31,599 | $756.2K | — | |
SDGR | Karen Akinsanya | President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships | Mar 5, 2026 | Sale | $12.90 | 1,366 | $17.6K | 69,956 | |
SDGR | Akinsanya Karen | — | Mar 5, 2026 | Proposed Sale | $12.90 | 1,366 | $17.6K | — | |
SDGR | Karen Akinsanya | President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships | Mar 2, 2026 | Sale | $11.99 | 2,206 | $26.5K | 71,322 | |
SDGR | Akinsanya Karen | — | Mar 2, 2026 | Proposed Sale | $11.99 | 2,206 | $26.5K | — | |
SDGR | Karen Akinsanya | — | Apr 14, 2025 | Proposed Sale | $24.49 | 16,723 | $409.5K | — |